Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study
Based on this analysis, sequencing vedolizumab as a first-line biologic prior to anti-TNFα in UC and CD provided additional clinical benefit to patients. In UC, vedolizumab as a first-line biologic also saved healthcare system costs compared with anti-TNFα, whereas in CD, vedolizumab provided incremental benefit at an incremental cost, which was not considered cost effective at a threshold of $50,000/QALY.
Authors
- Aren Fischer
- John K. Marshall (ORCID: https://orcid.org/0000-0002-0523-9032)
- Kim Rand (ORCID: https://orcid.org/0000-0001-7692-4099)
- Juan Manuel Ramos-Goñi (ORCID: https://orcid.org/0000-0002-9568-5190)
- Stephen Mac (ORCID: https://orcid.org/0000-0003-4736-1770)
- Erica Stivelman Freiman
Institutions
- Population Health Research Institute (CA)
- Alexion Pharmaceuticals (United States) (US)
- Takeda (Canada) (CA)
- Alexion Pharma (Switzerland) (CH)
- McMaster University (CA)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1007/s41669-024-00523-5
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- Takeda Canada